Eric Chatelain

5.5k total citations · 1 hit paper
63 papers, 3.6k citations indexed

About

Eric Chatelain is a scholar working on Epidemiology, Public Health, Environmental and Occupational Health and Organic Chemistry. According to data from OpenAlex, Eric Chatelain has authored 63 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Epidemiology, 45 papers in Public Health, Environmental and Occupational Health and 30 papers in Organic Chemistry. Recurrent topics in Eric Chatelain's work include Trypanosoma species research and implications (46 papers), Research on Leishmaniasis Studies (44 papers) and Synthesis and Biological Evaluation (26 papers). Eric Chatelain is often cited by papers focused on Trypanosoma species research and implications (46 papers), Research on Leishmaniasis Studies (44 papers) and Synthesis and Biological Evaluation (26 papers). Eric Chatelain collaborates with scholars based in Switzerland, United States and United Kingdom. Eric Chatelain's co-authors include B. Gabard, Lúcio H. Freitas-Júnior, C Wirbelauer, Hedwig Sutterlüty, Uli Müller, Jean‐Robert Ioset, Jair L. Siqueira-Neto, Helena Andrade, Christian Surber and Daniel Boscoboinik and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Eric Chatelain

62 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells

1999 610 citations Hedwig Sutterlüty, Eric Chatelain et al. Nature Cell Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric Chatelain Switzerland	31	1.7k	1.6k	1.2k	1.1k	487	63	3.6k
Hassan Jomaa Germany	45	512 0.3×	1.6k 1.0×	827 0.7×	3.6k 3.2×	407 0.8×	129	6.4k
Pijush K. Das India	33	665 0.4×	949 0.6×	227 0.2×	1.2k 1.1×	260 0.5×	113	3.0k
Syamal Roy India	35	1.6k 0.9×	2.5k 1.5×	404 0.3×	959 0.9×	158 0.3×	106	3.8k
Subrata Majumdar India	34	771 0.4×	947 0.6×	201 0.2×	1.2k 1.1×	256 0.5×	107	3.1k
Kohei Yokoyama United States	30	389 0.2×	510 0.3×	754 0.6×	1.5k 1.3×	269 0.6×	68	2.6k
Dunne Fong United States	33	658 0.4×	805 0.5×	234 0.2×	1.2k 1.1×	231 0.5×	60	3.0k
Hemanta K. Majumder India	33	879 0.5×	1.6k 1.0×	1.0k 0.9×	2.1k 1.9×	352 0.7×	109	3.7k
Nicoletta Basilico Italy	35	286 0.2×	1.5k 0.9×	1.2k 1.0×	880 0.8×	288 0.6×	142	3.6k
José Andrés Morgado‐Díaz Brazil	32	471 0.3×	448 0.3×	243 0.2×	1.6k 1.4×	502 1.0×	87	3.2k
Ying‐Ray Lee Taiwan	30	544 0.3×	572 0.3×	171 0.1×	1.0k 0.9×	233 0.5×	91	2.5k

Countries citing papers authored by Eric Chatelain

Since Specialization

Citations

This map shows the geographic impact of Eric Chatelain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Chatelain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Chatelain more than expected).

Fields of papers citing papers by Eric Chatelain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Chatelain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Chatelain. The network helps show where Eric Chatelain may publish in the future.

Co-authorship network of co-authors of Eric Chatelain

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Chatelain. A scholar is included among the top collaborators of Eric Chatelain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Chatelain. Eric Chatelain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Touret, Franck, Jean‐Sélim Driouich, Maxime Cochin, et al.. (2024). Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns. Heliyon. 10(10). e30862–e30862. 2 indexed citations

Scandale, Ivan, et al.. (2024). Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay. Nature Communications. 15(1). 10530–10530. 1 indexed citations

Gabaldón-Figueira, Juan Carlos, Eric Chatelain, Ivan Scandale, et al.. (2023). State-of-the-Art in the Drug Discovery Pathway for Chagas Disease: A Framework for Drug Development and Target Validation. PubMed Central. Volume 14. 1–19. 20 indexed citations

Francisco, Amanda Fortes, Gong� Chen, Wen Wang, et al.. (2023). Preclinical data do not support the use of amiodarone or dronedarone as antiparasitic drugs for Chagas disease at the approved human dosing regimen. SHILAP Revista de lepidopterología. 4. 2 indexed citations

Golizeh, Makan, Eric Chatelain, Yves Jackson, et al.. (2022). New metabolic signature for Chagas disease reveals sex steroid perturbation in humans and mice. Heliyon. 8(12). e12380–e12380. 12 indexed citations

Thompson, Andrew M., P. D. T. O’Connor, Vanessa Yardley, et al.. (2021). Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility. ACS Medicinal Chemistry Letters. 12(2). 275–281. 10 indexed citations

Franco, Caio Haddad, David C. Warhurst, Tapan Bhattacharyya, et al.. (2020). Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity. International Journal for Parasitology Drugs and Drug Resistance. 13. 107–120. 11 indexed citations

Thompson, Andrew M., P. D. T. O’Connor, Andrew J. Marshall, et al.. (2020). Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal. European Journal of Medicinal Chemistry. 209. 112914–112914. 17 indexed citations

Zrein, Maan & Eric Chatelain. (2019). The unmet medical need for Trypanosoma cruzi-infected patients: Monitoring the disease status. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1866(3). 165628–165628. 5 indexed citations

10.

Hennig, K, Josephine Abi‐Ghanem, Michael D. Lewis, et al.. (2019). Metabolomics, lipidomics and proteomics profiling of myoblasts infected with Trypanosoma cruzi after treatment with different drugs against Chagas disease. Metabolomics. 15(9). 117–117. 19 indexed citations

11.

Francisco, Amanda Fortes, Shiromani Jayawardhana, Michael D. Lewis, et al.. (2016). Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage. Scientific Reports. 6(1). 35351–35351. 69 indexed citations

12.

Papadopoulou, Maria V., William D. Bloomer, Howard S. Rosenzweig, et al.. (2015). Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation. Bioorganic & Medicinal Chemistry. 23(19). 6467–6476. 37 indexed citations

13.

Chatelain, Eric. (2014). Chagas Disease Drug Discovery: Toward a New Era. SLAS DISCOVERY. 20(1). 22–35. 212 indexed citations

14.

Keenan, Martine, Paul W. Alexander, Wayne M. Best, et al.. (2013). Design, structure–activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi. Bioorganic & Medicinal Chemistry. 21(7). 1756–1763. 27 indexed citations

15.

Sykes, Melissa L., Jonathan B. Baell, Marcel Kaiser, et al.. (2012). Identification of Compounds with Anti-Proliferative Activity against Trypanosoma brucei brucei Strain 427 by a Whole Cell Viability Based HTS Campaign. PLoS neglected tropical diseases. 6(11). e1896–e1896. 70 indexed citations

16.

Siqueira-Neto, Jair L., Ok‐Ryul Song, Jeong‐Hun Sohn, et al.. (2010). Antileishmanial High-Throughput Drug Screening Reveals Drug Candidates with New Scaffolds. PLoS neglected tropical diseases. 4(5). e675–e675. 127 indexed citations

17.

Gabard, B., et al.. (2001). Surfactant irritation: in vitro corneosurfametry and in vivo bioengineering. Skin Research and Technology. 7(1). 49–55. 22 indexed citations

18.

Sutterlüty, Hedwig, et al.. (1999). p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nature Cell Biology. 1(4). 207–214. 610 indexed citations breakdown →

19.

Mathieu, Marc, Eric Chatelain, David M. Ornitz, et al.. (1995). Receptor Binding and Mitogenic Properties of Mouse Fibroblast Growth Factor 3. Journal of Biological Chemistry. 270(41). 24197–24203. 50 indexed citations

20.

Boscoboinik, Daniel, et al.. (1994). Inhibition of protein kinase C activity and vascular smooth muscle cell growth by d-α-tocopherol. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1224(3). 418–426. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact